Quintana-Ortega Cristian, Prieto-Moreno Pfeifer Ana, Palomino Lozano Laura, Lancharro Ángel, Saavedra Lozano Jesús, Villa-García Ángel José, Seoane-Reula Elena
Pediatric Rheumatology Department, La Paz Children´s Hospital, Madrid, Spain.
Department of Allergy, Infanta Leonor University Hospital, Madrid, Spain.
Mod Rheumatol Case Rep. 2023 Jan 3;7(1):215-218. doi: 10.1093/mrcr/rxac010.
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare idiopathic autoinflammatory bone disease characterised by noninfective inflammation of bones. Diagnostic approach is challenging and requires exclusion of other causes such as malignancies or infections. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are usually applied as first-line therapy in CRMO patients; however, some cases require more intensive therapy with second-line agents to control disease activity. We hereby describe the use of colchicine as a nonconventional second-line disease-modifying antirheumatic drug in two pediatric patients with CRMO refractory to NSAIDs and corticosteroids. Our data indicate that colchicine might prove an important area for future research as a potential therapeutic option with easy administration, low cost, and a good safety profile in CRMO patients refractory to first-line therapy.
慢性复发性多灶性骨髓炎（CRMO）是一种罕见的特发性自身炎症性骨病，其特征为骨的非感染性炎症。诊断方法具有挑战性，需要排除其他病因，如恶性肿瘤或感染。非甾体类抗炎药（NSAIDs）和皮质类固醇通常作为CRMO患者的一线治疗药物；然而，一些病例需要使用二线药物进行更强化的治疗以控制疾病活动。我们在此描述了秋水仙碱在两名对NSAIDs和皮质类固醇治疗无效的CRMO儿科患者中作为一种非传统的二线改善病情抗风湿药物的应用。我们的数据表明，秋水仙碱作为一种潜在的治疗选择，给药方便、成本低且安全性良好，对于一线治疗无效的CRMO患者可能是未来研究的一个重要领域。
